Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHATHOM PHARMACEUTICALS, INC.

(PHAT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

10/18/2021 | 07:00am EST

Phathom Pharmaceuticals, Inc. announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal phase 3 trial evaluating vonoprazan versus lansoprazole for the treatment of erosive esophagitis. Based on the positive PHALCON-EE data, Phathom plans to submit an NDA to the U.S. Food and Drug Administration seeking the following indications: healing of all grades of EE and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn. PHALCON-EE was a trial with two phases. In the first phase, vonoprazan 20 mg was compared to lansoprazole 30 mg in the healing of EE after up to 8 weeks of treatment (Healing Phase). In the Healing Phase, patients were assessed via endoscopy to determine complete healing following 2 weeks of treatment and, if complete healing was not achieved, a second endoscopy occurred at 8 weeks of treatment. Patients who achieved complete healing were re-randomized into the second phase of the trial, where vonoprazan 10 mg and 20 mg were compared to lansoprazole 15 mg to assess maintenance of healing via endoscopy following 24 weeks of treatment (Maintenance Phase). Heartburn symptom relief was assessed via secondary endpoints in both the Healing and Maintenance Phases of the study based on twice daily e-diary data collection. The primary endpoint of the Healing Phase was non-inferiority of vonoprazan 20 mg compared to lansoprazole 30 mg in the percentage of all patients who have complete healing of EE by Week 8. Vonoprazan met the Healing Phase primary endpoint with a healing rate of 93% compared to 85% for lansoprazole (p


ę S&P Capital IQ 2021
All news about PHATHOM PHARMACEUTICALS, INC.
11/23Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Confer..
AQ
11/12Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
GL
11/08Phathom Pharmaceuticals Narrows Q3 Net Loss Per Share
MT
11/08PHATHOM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
AQ
11/08Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, R..
PU
11/08Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, R..
AQ
11/08Earnings Flash (PHAT) PHATHOM PHARMACEUTICALS Posts Q3 Loss $-0.98
MT
11/08Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine M..
CI
10/27Phathom Pharmaceuticals Withdraws Public Offering
GL
10/27Health Care Stocks Slide Wednesday as Biotechs Weigh on Sector
MT
More news
Analyst Recommendations on PHATHOM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -143 M - -
Net cash 2021 127 M - -
P/E ratio 2021 -4,83x
Yield 2021 -
Capitalization 567 M 567 M -
EV / Sales 2021 -
EV / Sales 2022 73,8x
Nbr of Employees 55
Free-Float 81,7%
Chart PHATHOM PHARMACEUTICALS, INC.
Duration : Period :
Phathom Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHATHOM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 18,73 $
Average target price 57,40 $
Spread / Average Target 206%
EPS Revisions
Managers and Directors
Terrie Curran President, Chief Executive Officer & Director
Anthony J. Guzzo VP, Chief Financial & Accounting Officer
Eckhard S. D. Leifke Chief Medical Officer
Azmi Nabulsi Chief Operating Officer
Joseph Hand Chief Administrative Officer
Sector and Competitors
1st jan.Capi. (M$)
PHATHOM PHARMACEUTICALS, INC.-43.62%567
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888